Summary
Justin Kim is a corporate development professional with 11 years of experience at the intersection of life sciences, strategy, and finance, currently pursuing an MBA/MPH at Yale while holding roles at RTW Investments and Kanoma Capital. He has led deal and launch strategy work across biotech and pharma—from pipeline and launch strategy at ZS to BD/finance at Oncoceutics and corporate development at Roivant—contributing to transactions including an acquisition by Chimerix. Trained in Mathematical Biology, Health Care Management & Policy, and Statistics at Penn, he blends quantitative rigor with commercial insight to evaluate programs and structure partnerships. His recent summer in Health Futures Strategy at Microsoft and continued venture activity via Yale Ventures signal a growing focus on strategic investment and health innovation. Colleagues describe him as analytically disciplined yet adept at translating complex clinical and market data into actionable business plans. He is based in New Haven and uniquely combines front-line biotech deal experience with formal public health and business training.
12 years of coding experience
5 years of employment as a software developer
Flatiron School
MPH (Biostatistics)/MBA, MPH (Biostatistics)/MBA at Yale University
Bachelor’s Degree, Economics (Concentrations in Healthcare Management and Policy, Statistics), Bachelor’s Degree, Economics (Concentrations in Healthcare Management and Policy, Statistics) at University of Pennsylvania - The Wharton School
Bachelor’s Degree, Mathematical Biology, Bachelor’s Degree, Mathematical Biology at University of Pennsylvania
High School Diploma, Medical Science Technology, High School Diploma, Medical Science Technology at Academy for Medical Science Technology
English, Korean